The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer

Derek J. Erstad, Andrew M. Tager, Yujin Hoshida, Bryan C. Fuchs

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals, identifying ATX-LPA signaling as a novel chemoprevention strategy for cirrhosis and HCC.

Original languageEnglish (US)
Article numbere1311827
JournalMolecular and Cellular Oncology
Volume4
Issue number3
DOIs
StatePublished - May 4 2017
Externally publishedYes

Fingerprint

Liver Neoplasms
Hepatocellular Carcinoma
Fibrosis
Chemoprevention
Gene Expression Profiling
Meta-Analysis
Therapeutics
Pharmacology
lysophosphatidic acid

Keywords

  • ATX
  • chemoprevention
  • cirrhosis
  • fibrosis
  • HCC
  • hepatocellular carcinoma
  • LPA
  • LPAR1
  • NASH
  • non-alcoholic steatohepatitis

ASJC Scopus subject areas

  • Molecular Medicine
  • Cancer Research

Cite this

The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer. / Erstad, Derek J.; Tager, Andrew M.; Hoshida, Yujin; Fuchs, Bryan C.

In: Molecular and Cellular Oncology, Vol. 4, No. 3, e1311827, 04.05.2017.

Research output: Contribution to journalArticle

@article{4d471934d0134d81aa20699980734e46,
title = "The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer",
abstract = "Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals, identifying ATX-LPA signaling as a novel chemoprevention strategy for cirrhosis and HCC.",
keywords = "ATX, chemoprevention, cirrhosis, fibrosis, HCC, hepatocellular carcinoma, LPA, LPAR1, NASH, non-alcoholic steatohepatitis",
author = "Erstad, {Derek J.} and Tager, {Andrew M.} and Yujin Hoshida and Fuchs, {Bryan C.}",
year = "2017",
month = "5",
day = "4",
doi = "10.1080/23723556.2017.1311827",
language = "English (US)",
volume = "4",
journal = "Molecular and Cellular Oncology",
issn = "2372-3556",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer

AU - Erstad, Derek J.

AU - Tager, Andrew M.

AU - Hoshida, Yujin

AU - Fuchs, Bryan C.

PY - 2017/5/4

Y1 - 2017/5/4

N2 - Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals, identifying ATX-LPA signaling as a novel chemoprevention strategy for cirrhosis and HCC.

AB - Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals, identifying ATX-LPA signaling as a novel chemoprevention strategy for cirrhosis and HCC.

KW - ATX

KW - chemoprevention

KW - cirrhosis

KW - fibrosis

KW - HCC

KW - hepatocellular carcinoma

KW - LPA

KW - LPAR1

KW - NASH

KW - non-alcoholic steatohepatitis

UR - http://www.scopus.com/inward/record.url?scp=85037622026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037622026&partnerID=8YFLogxK

U2 - 10.1080/23723556.2017.1311827

DO - 10.1080/23723556.2017.1311827

M3 - Article

C2 - 28616586

AN - SCOPUS:85037622026

VL - 4

JO - Molecular and Cellular Oncology

JF - Molecular and Cellular Oncology

SN - 2372-3556

IS - 3

M1 - e1311827

ER -